Skip to main content

Table 2 Association between expression of sex hormone receptors and clinicopathological characteristics in gastric cancer

From: Expression profile and prognostic role of sex hormone receptors in gastric cancer

Variable

Total patients (n = 866)

Evaluable patients†

ERα (n = 848)

ERβ (n = 823)

PR (n = 851)

AR (n = 843)

Positive No. (%)

P

Positive No. (%)

P

Positive No. (%)

P

Positive No. (%)

P

Sex

  

0.496

 

0.166

 

0.522

 

0.313

 Female

261

29 (10.9)

 

221 (89.8)

 

58 (21.9)

 

81 (30.6)

 

 Male

605

73 (12.5)

 

535 (92.7)

 

140 (23.9)

 

197 (34.1)

 

Age, years

  

0.837

 

0.187

 

0.523

 

0.254

 ≤40

70

6 (8.8)

 

57 (87.7)

 

12 (17.6)

 

16 (24.2)

 

 ≤50

148

19 (13.2)

 

126 (93.3)

 

30 (20.7)

 

46 (32.2)

 

 ≤65

328

39 (12.0)

 

283 (90.1)

 

79 (24.5)

 

102 (31.9)

 

 >65

320

38 (12.2)

 

290 (93.9)

 

77 (24.4)

 

114 (36.3)

 

Tumor site§

  

0.839

 

0.700

 

0.433

 

0.605

 Upper

138

19 (13.8)

 

123 (91.8)

 

25 (18.2)

 

52 (38.0)

 

 Middle

263

30 (11.8)

 

224 (90.3)

 

63 (24.3)

 

81 (31.9)

 

 Lower

416

46 (11.3)

 

368 (92.9)

 

100 (24.6)

 

129 (32.0)

 

 Diffuse

49

7 (14.3)

 

41 (91.1)

 

10 (20.4)

 

16 (32.7)

 

Tumor size, cm

  

0.166

 

0.316

 

0.425

 

0.127

 ≤2

133

22 (17.1)

 

117 (95.9)

 

28 (22.0)

 

52 (42.3)

 

 ≤3

160

21 (13.7)

 

134 (89.9)

 

29 (18.6)

 

50 (32.3)

 

 ≤5

273

30 (11.1)

 

243 (91.7)

 

67 (24.7)

 

84 (31.3)

 

 >5

300

29 (9.8)

 

262 (91.3)

 

74 (24.9)

 

92 (31.0)

 

Tumor grade

  

<0.001

 

0.030

 

0.001

 

<0.001

 Well

48

15 (31.9)

 

53 (96.4)

 

19 (40.4)

 

22 (48.9)

 

 Moderate

286

47 (16.5)

 

274 (94.5)

 

77 (27.1)

 

127 (44.9)

 

 Poor

532

40 (7.8)

 

429 (89.7)

 

102 (19.6)

 

129 (25.0)

 

Lauren type

  

0.012

 

0.010

 

0.017

 

<0.001

 Intestinal

535

76 (14.4)

 

481 (93.0)

 

139 (26.3)

 

197 (37.6)

 

 Diffuse

297

21 (7.4)

 

250 (91.2)

 

55 (19.0)

 

68 (23.9)

 

 Mixed

34

5 (14.7)

 

25 (78.1)

 

4 (11.8)

 

13 (38.2)

 

T classification¶

  

<0.001

 

0.195

 

0.818

 

<0.001

 pT1

132

33 (26.0)

 

114 (95.0)

 

28 (21.7)

 

61 (48.8)

 

 pT2

142

19 (13.9)

 

125 (94.7)

 

36 (26.3)

 

49 (36.6)

 

 pT3

528

44 (8.4)

 

463 (90.8)

 

120 (23.0)

 

147 (28.2)

 

 pT4

64

6 (9.7)

 

54 (88.5)

 

14 (22.2)

 

21 (33.9)

 

N classification¶

  

<0.001

 

0.574

 

0.340

 

0.001

 pN0

309

67 (22.3)

 

272 (93.2)

 

76 (25.0)

 

125 (41.9)

 

 pN1

314

20 (6.5)

 

275 (90.2)

 

63 (20.7)

 

85 (28.0)

 

 pN2

191

13 (6.9)

 

165 (92.7)

 

43 (22.6)

 

52 (27.4)

 

 pN3

52

2 (3.9)

 

44 (91.7)

 

16 (30.8)

 

16 (31.4)

 

TNM stage¶

  

<0.001

 

0.173

 

0.535

 

<0.001

 I

187

44 (24.4)

 

165 (95.4)

 

48 (26.2)

 

85 (47.8)

 

 II

158

21 (13.5)

 

138 (90.8)

 

39 (25.3)

 

53 (35.1)

 

 III

294

23 (8.0)

 

253 (89.7)

 

61 (21.0)

 

74 (25.3)

 

 IV

227

14 (6.3)

 

200 (92.6)

 

50 (22.3)

 

66 (29.7)

 
  1. ERα, estrogen receptor alpha; ERβ, estrogen receptor beta; PR, progesterone receptor; AR, androgen receptor. †Total patients except for inevaluable cases due to tissue loss or inadequate tissue in immunohistochemistry assay. ‡Chi-square test. §Japanese Classification of Gastric Carcinoma (3rd English edition) proposed by the Japanese Gastric Cancer Association (JGCA). ¶The 6th TNM Classification of Malignant Tumors proposed by the AJCC/UICC.